Celgene vs. Gilead Sciences: Who Reported Better Earnings?

Celgene vs. Gilead Sciences: Who Reported Better Earnings?

Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very different. While Celgene is racking up substantial growth for its top-selling medicines, Gilead Sciences is navigating an increasingly competitive market for its hepatitis C drugs. Are these companies on the right track?

In this episode of the Motley Fool's Industry Focus: Healthcare podcast, Foolish investors Kristine Harjes and Todd Campbell discuss the companies' second-quarter earnings results and what's next for these two big-cap biotech stocks.

Also, Kristine and Todd weigh in on the rapidly evolving market for non-small cell lung cancer treatment, providing insight into the latest quarterly performance for Merck & Co.'s (NYSE: MRK) Keytruda and Bristol-Myers Squibb's (NYSE: BMY) Opdivo.

Continue reading

Source: Fool.com